The prevalence of NAFLD was similar across the three different indicators (2.3%, 3.1% and 2.3%, for USS steatosis, elevated ALT (>40 U/l) and elevated AST (>40 U/l), respectively), but with varying levels of overlap in cases across the measures. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.